What is the primary purpose of this debt offering?

The primary purpose of this debt offering is to refinance existing debt. The net proceeds are intended to be used for the redemption and/or repayment of a portion of Abbott's outstanding 2.900% Notes due 2021, including any associated premiums, accrued interest, and expenses.

Are these notes eligible for purchase by U.S. investors?

The notes were offered and sold under Regulation S, which is exempt from the registration requirements of the Securities Act of 1933. Therefore, they may not be offered or sold in the United States or to U.S. persons, absent registration or an applicable exemption.

What kind of covenants are included in the indenture related to this debt?

The indenture includes covenants that restrict Abbott and its domestic subsidiaries from incurring additional secured indebtedness without providing equal and ratable security for the guarantee, and also limits certain sale and leaseback transactions involving principal domestic properties. There are also restrictions on the Issuer creating mortgages on its assets to secure certain listed or traded debt.

ABT 8-K SEC Disclosure — Nov 19, 2019

Q: What are the terms of the newly issued notes?

Abbott issued two series of notes: €590 million of 0.100% Notes due 2024 and €590 million of 0.375% Notes due 2027. These notes are guaranteed by Abbott Laboratories and are unsecured and unsubordinated debt obligations.

Summary

Abbott Laboratories (ABT) announced the completion of a significant debt offering on November 19, 2019, through its indirect wholly-owned subsidiary, Abbott Ireland Financing DAC. The company successfully issued €1.18 billion in aggregate principal amount of notes, split between €590 million of 0.100% Notes due 2024 and €590 million of 0.375% Notes due 2027. These notes are guaranteed by Abbott Laboratories and are unsecured and unsubordinated debt obligations. The net proceeds from this offering are earmarked for redeeming and/or repaying a portion of Abbott's outstanding 2.900% Notes due 2021, including associated premiums and expenses. This transaction represents a strategic move to refinance existing debt with lower interest rates, potentially improving the company's interest expense over the medium term. While the notes are unsecured, Abbott has included covenants that restrict the incurrence of additional secured debt by the company and its domestic subsidiaries and limit certain sale and leaseback transactions. Investors should note that the offering was made pursuant to Regulation S and is exempt from the registration requirements of the Securities Act of 1933, meaning they were not offered or sold to U.S. persons in the United States.

Key Highlights

1Abbott Ireland Financing DAC, an indirect wholly-owned subsidiary of Abbott Laboratories, completed a debt offering on November 19, 2019.
2The offering consisted of €590 million of 0.100% Notes due 2024 and €590 million of 0.375% Notes due 2027, totaling €1.18 billion.
3The Notes are unconditionally guaranteed by Abbott Laboratories.
4The Notes are unsecured and unsubordinated debt obligations.
5Proceeds from the offering will be used to redeem and/or repay a portion of Abbott's outstanding 2.900% Notes due 2021.
6The debt offering was exempt from U.S. Securities Act registration requirements under Regulation S.
7The indenture includes covenants restricting the incurrence of additional secured debt and certain sale and leaseback transactions.

ABBOTT LABORATORIES 8-K Report, Corporate Update (Nov 19, 2019)

Summary

Key Highlights

Frequently Asked Questions